LOGIN  |  REGISTER
Assertio
C4 Therapeutics

Amwell to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences

October 27, 2025 | Last Trade: US$4.21 0.11 2.68

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report third quarter 2025 operating results after stock market trading hours on Tuesday, Nov. 4.

Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update.

The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days.

In addition, company executives will attend these upcoming investor conferences:

  • Mark Hirschhorn, CFO and COO, will participate in one-on-one meetings at the UBS Global Healthcare Conference on Nov. 11 in Palm Beach Gardens. Fl.
  • Mark Hirschhorn, will participate in a panel discussion titled “Transforming a Sick-Care System into a Health-Care System,” taking place virtually at 8:00 a.m. ET at the BTIG Digital Health Forum on Nov. 24.

An audio webcast of the fireside chat will be available at investors.amwell.com.

About Amwell  

Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.

Investors:
Asher Dewhurst
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media:
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page